Immunome (NASDAQ:IMNM) Shares Down 3.3%

Immunome, Inc. (NASDAQ:IMNM) was down 3.3% on Friday . The stock traded as low as $16.44 and last traded at $16.61. Approximately 316,731 shares traded hands during trading, a decline of 54% from the average daily volume of 692,392 shares. The stock had previously closed at $17.18.

Analyst Upgrades and Downgrades

IMNM has been the topic of several analyst reports. Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a report on Monday, January 29th. Guggenheim initiated coverage on Immunome in a report on Monday. They issued a “buy” rating and a $35.00 target price on the stock. SVB Leerink initiated coverage on Immunome in a report on Monday, January 29th. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, Wedbush boosted their target price on Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a report on Monday, April 1st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $32.67.

Immunome Stock Down 6.6 %

The stock has a market capitalization of $957.43 million, a P/E ratio of -3.00 and a beta of 1.66. The business has a fifty day moving average price of $23.03 and a 200-day moving average price of $14.81.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada lifted its holdings in shares of Immunome by 3.2% during the fourth quarter. Royal Bank of Canada now owns 29,484 shares of the company’s stock valued at $315,000 after purchasing an additional 928 shares in the last quarter. BlackRock Inc. increased its position in Immunome by 4.3% during the second quarter. BlackRock Inc. now owns 43,312 shares of the company’s stock valued at $343,000 after acquiring an additional 1,773 shares during the last quarter. HighTower Advisors LLC increased its position in Immunome by 19.0% during the third quarter. HighTower Advisors LLC now owns 18,818 shares of the company’s stock valued at $157,000 after acquiring an additional 3,000 shares during the last quarter. Dorsey Wright & Associates purchased a new stake in Immunome during the third quarter valued at $26,000. Finally, Vanguard Group Inc. increased its position in Immunome by 0.8% during the third quarter. Vanguard Group Inc. now owns 373,685 shares of the company’s stock valued at $1,659,000 after acquiring an additional 3,149 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.